Evidence map›Paper›PMID 29143247›Full record

ArticleImmunologic research2018

Using circulating tumor cells to evaluate the efficacy of irreversible electroporation for unresectasble pancreatic cancer.

Mao Lin, Mohammed Alnaggar, Shu-Zhen Liang, Jian Shi, Li-Zhi Niu, Ji-Bing Chen, Ke-Cheng Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mao LinDepartment of Biological Treatment Center, Fuda Cancer Hospital, Jinan University, Jinan, China.
Mohammed AlnaggarDepartment of Biological Treatment Center, Fuda Cancer Hospital, Jinan University, Jinan, China.
Shu-Zhen LiangDepartment of Biological Treatment Center, Fuda Cancer Hospital, Jinan University, Jinan, China.
Jian ShiDepartment of General Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China.
Li-Zhi NiuDepartment of Biological Treatment Center, Fuda Cancer Hospital, Jinan University, Jinan, China. 18922210657@163.com.
Ji-Bing ChenDepartment of Biological Treatment Center, Fuda Cancer Hospital, Jinan University, Jinan, China. linmaogz@163.com.ORCID 0000-0001-8596-2126
Ke-Cheng XuDepartment of Biological Treatment Center, Fuda Cancer Hospital, Jinan University, Jinan, China.

Funding

International Scientific Fund of Fuda Cancer Hospital, Guangzhou Y2016-ZD-003
6 · The paper itself

Abstract

We used circulating tumor cells (CTCs) as biomarkers to evaluate the efficacy of pre-irreversible electroporation (IRE) and post-IRE for unresectable pancreatic cancer (PC). Real-time qPCR was used to detect potential biomarker genes in CTCs, and magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS) were performed on 43 patients with PC who underwent IRE. Some patients experienced adverse reactions within 30 days of the operation, including arrhythmia (6.9%), intraoperative transient change of blood pressure (25.5%), cough (11.6%), nausea and vomiting (23.3%), ascites (25.6%), fever (9.3%), and pain of puncture point (60.5%). The number of CTCs decreased significantly with postoperative time (P < 0.01). Delta cycle threshold values for the CTC-related genes CEA, Ep-CAM, and CK19 increased significantly after IRE. Furthermore, the expression of CEA, Ep-CAM, and CK19 decreased significantly with time after IRE (P < 0.01). Detecting CTCs by RT-qPCR and FACS combined with MACS has significant diagnostic and prognostic value for evaluating the efficacy of IRE in patients with unresectable PC.

Indexed as

ElectroporationAblation TechniquesAdultAgedAged, 80 and overBiomarkersCell CountChinaHumansInjection Site ReactionMiddle AgedNeoplastic Cells, CirculatingPancreatic NeoplasmsPostoperative ComplicationsPostoperative Nausea and VomitingSurgery, Computer-AssistedBiomarkersBiomarkerCirculating tumor cellsEfficacyReal-time quantitative PCRUnresectable pancreatic cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.